Biomerica, Inc. (NASDAQ: BMRA) has reported entry into a General Merchandise Supplier Agreement with Walmart for the sale of the Company’s EZ Detector colorectal disease screening test within Walmart’s retail system. Biomerica has shipped its first orders of the EZ Detect product to Walmart, starting this week Walmart has begun selling its product through its online sales channel.
The EZ Detector colon disease screening test touts its simplicity to test to detector occult blood at home in a person’s stool which may indicate early signs of colorectal disease including colon and rectal cancers.
“With the current COVID-19 pandemic, consumers have become much more aware of at-home diagnostic testing and are more comfortable performing these tests. For this reason, many global retailers are expanding their focus on selling home health solutions. This growing trend presents many opportunities for our EZ Detect™ colorectal disease test, our Aware™ breast self-exam product and other products that we make for in-home use. While there are other choices for colorectal disease screening, EZ Detect™ offers the only alternative that doesn’t require handling of the stool, making our test more appealing and easier to conduct from the consumer perspective. In addition, the agreement for online sales of EZ Detect with Walmart could bring significant exposure to the product here in the US,” commented Zack Irani, CEO of Biomerica.